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Themajorobstacleinplatinum chemotherapyistherepairofplatinum-damagedDNA thatresultsinincreased resistance,reduced
apoptosis, and ﬁnally treatment failure. Our research goal is to determine and block the mechanisms of platinum resistance. Our
recent studies demonstrate that several kinases in the DNA-repair pathway are activated after cells are exposed to cisplatin. These
include ATM, p53, andChk2.The increasedChk2 phosphorylationis modulated by p53 ina wild-type p53 model. Overexpression
of p53 by cDNA transfection in wt-p53 (but not p53 deﬁcient) cells doubled the amount of Chk2 phosphorylation 48 hours after
cisplatin treatment. p53 knockdown by speciﬁc siRNA greatly reduced Chk2phosphorylation.We conclude that wild-type p53, in
responseto cisplatinstimulation,plays arole intheupstream regulationofChk2phosphorylationatThr-68.Cells withoutnormal
p53 function survive via an alternative pathway in response to the exogenous inﬂuence of cisplatin. We strongly suggest that it is
very important to include the p53 mutationalstatus in any p53 involved studies due to the functional diﬀerentiation of wt p53 and
p53 mutant.Inhibition of Chk2 pathwaywith a Chk2 inhibitor (C3742) increased cisplatin eﬃcacy, especially those with defective
p53. Our ﬁndings suggest that inhibition of platinum resistance can be achieved with a small-molecule inhibitor of Chk2, thus
improving the therapeutic indices for platinum chemotherapy.
1.Introduction
DNA targeting agents for cancer treatment are among the
most common treatments to ﬁght cancer. However, side
eﬀects and drug resistance of chemotherapy are a major
clinical problem, seriously aﬀecting both the life quality
of patients and the outcome of treatment. Studies show
that cells treated with genotoxic agents swiftly respond by
activating DNA-damage checkpoint response. This prompts
the repair of DNA lesions while transiently slowing down
replication, or it elicits an apoptotic program in case of
massive or irreparable lesions to the DNA. Two primary
pathways are initiated in response to DNA damage. One is
mediated by the ATM-Chk2 axis and the other, via the ATR-
Chk1 axis. The ATM/Chk2 pathway responds primarily to
DNA double-strand breaks, whereas the ATR-Chk1 pathway
mainlyrespondstoreplication-associatedDNAlesions[1,2].
The transcription factor p53, a DNA-binding protein
containing DNA-binding, oligomerization, and transcrip-
tional activation domains [3–6], plays a key role in the DNA
damage response to genotoxic stress by binding directly to
the promoters of target genes and altering the rate at which
they are transcribed [7, 8]. Under normal conditions wild-
type p53 is maintained at a low level due to the extremely2 Chemotherapy Research and Practice
short half-life of the polypeptide, and in a largely inactive
state that is ineﬃcient for its function [7–10]. In response to
genotoxic stress, wt p53 proteins form a tetramer that binds
DNA for exerting its transactivate function [6, 11]. This will
lead to the activation of numerous genes that cause growth
arrest and apoptosis [7–11].
Checkpoint kinase 2 (Chk2), a serine/threonine kinase
and encoded protein, contains a forkhead-associated protein
interaction domain. It lies at the heart of the DNA dam-
age/repair pathway and is responsible for the maintenance
of mammalian genomic integrity. Following exposure to
ionizing radiation, Chk2 is rapidly activated by ATM and
DNA-PK (DNA-dependent protein kinase) via phosphory-
lation at Thr68 of Chk2, causing homodimerization and
subsequent trans-activating autophosphorylations at Thr383
and Thr387 and cis-phosphorylation at Ser516 [1, 2, 12].
Chk2 activation occurs in an ATM-independent manner in
response to UV radiation or stalled DNA replication [13]. In
turn, activated Chk2 phosphorylates downstream substrates,
including Cdc25A on serine123 and Cdc25C on Ser215,a n d
inhibits Cdc25C phosphatase, preventing entry into mitosis,
leading to cell cycle arrest in G1 phase. This protein also
interacts with and phosphorylates BRCA1, allowing it to
restore survival after DNA damage [2, 12, 14, 15].
Recent studies suggest that Chk2 inhibition in com-
bination with genotoxic agents might have therapeutic
value. Inhibition of Chk2 expression reduces DNA damage-
induced cell cycle checkpoints and enhances apoptosis in
p53-defective HEK-293 cells [12, 16]. Chk2 inhibition also
increases the level of mitotic catastrophe and sensitizes
proliferating cells to doxorubicin-induced apoptosis [17].
Molecular or genetic targeting of Chk2 prevents the release
of survivin from mitochondria and enhances DNA damage-
induced tumor cell apoptosis, thus inhibiting in vivo growth
of resistant tumors, providing a rational approach for
treating these tumors [18]. In addition to augmenting the
eﬀect of cytotoxic drugs, Chk2 inhibitors may elicit radio-
or chemoprotection of normal tissue via abrogation of p53-
dependent apoptosis [19].
This investigation focused on the cisplatin-induced
activation and regulation of Chk2 and further deﬁnes the
relationship between two central mediators, p53 and Chk2,
of the DNA damage/repair signaling pathway. Our results
suggest that, in speciﬁc conditions, Chk2 activation at Thr68
phosphorylation is regulated by p53 in response to cisplatin
treatment in wt p53-contain cells, but not in p53-deﬁcient
cells, of human ovarian cancer. Using a Chk2 inhibitor to
block this cellular pathway greatly enhanced the eﬃcacy of
cisplatin in cancer chemotherapy.
2.Materialsand Methods
2.1.CellCultureandDrugTreatment. Human ovarian cancer
cell lines A2780, Caov-3, and SKOV-3 were used in the
current investigation. Cells were cultured in monolayer
using RPMI 1640 media supplemented with 10% (v/v)
fetal calf serum, 2mM L-glutamine, 0.2units/mL human
insulin, 50units/mL penicillin, and 50mg/mL streptomycin
(Life Technologies, Inc., Gaithersburg, MD, USA). Cells
were grown in logarithmic growth at 37◦Ci nah u m i d i ﬁ e d
atmosphere consisting of 5% CO2, 95% air. Cells were
routinely recovered from frozen stocks and allowed to grow
until 80% conﬂuence. For all experiments, cells were plated
the day before exposure to treatment.
Cisplatin (CDDP) (Sigma-Aldrich, St. Louis, MO) was
prepared fresh daily by ﬁrst dissolving it in phosphate-
buﬀered saline (PBS), without Ca++ or Mg++,a tac o n -
centration of 1mg per ml, and then further diluting it
into prewarmed media to achieve the IC50 doses of 5-day
survival (3μM for A2780, 10μMf o rC a o v - 3 ,a n d7 5 μM
for SKOV-3 cells, resp.). For the time-course studies, cells
were allowed to grow for 24hr and treated with cisplatin for
1hratIC 50 doses. At the end of 1hr exposure to cisplatin,
cells were washed twice with PBS and then incubated with
fresh drug-free media for speciﬁcally required period of
time.
2.2. Protein Extraction and Western Blotting. Treated and
untreated cells were extracted with whole cell lysis buﬀer
(20mM Tris-HCl (pH 7.5), 150mM NaCl, 1mM Na2EDTA,
1mM EGTA, 1% Triton, 2.5mM sodium pyrophosphate,
β-glycerophosphate, 1mM Na3VO4,1m MP M S F ,1 0μg/mL
leupeptin, 10μg/mL aprotinin, and 5μg/mL pepstatin) for
30min before centrifugation (at 14,000rpm for 30min at
4◦C). Supernatant was collected as whole cell lysate for
Westernblotanalysis.Proteinconcentrationsofextractswere
determinedbyBio-RadProteinAssaykit(Bio-Rad,Hercules,
CA) with bovine serum albumin as standard.
The whole cell lysates were separated on 12% SDS-
polyacrylamide gels and transferred to PVDF membrane
(BIO-RAD) using standard electrophoresis and electroblot-
ting procedures. Prestained molecular weight markers were
purchased from Invitrogen (Carlsbad, CA). To reduce
nonspeciﬁc binding, blots were preincubated for 1hr in a
blocking buﬀer (5% nonfat dry milk, 1X TBS, and 0.1%
Tween 20). Membranes were then incubated with primary
antibodies overnight at 4◦C. The primary antibodies applied
were anti-ATM, anti-p-p53 phosphoserine-15, anti-p-p53
phosphoserine-20, anti-p53, anti-Chk2 phosphothreonine-
68, anti-Chk2, anti-P48, and anti-P21. To demonstrate an
equal loading of each sample, membranes were reprobed
with β-actin using anti-β-actin antibody (Sigma). The
signals of immunoreactive proteins were visualized using
horseradish peroxidase-conjugated sheep antimouse or don-
key antirabbit antibodies and enhanced by Chemilumines-
cence ECL detection system (Amersham, UK).
2.3. p53 Stable and Transient Transfection. A2780and SKOV-
3 cells were transfected with the plasmid pC53-SN3 or
pCMV-Neo-Bam (provided by Dr. Bert Vogelstein) for the
expression of wild-type human p53. Twenty-four hours after
transfection, cells were treated with cisplatin at IC50 doses
for 1hr and then were continuously incubated with fresh
media for indicated hours. Stable cell lines were established
by selection of positive transfected clones that grew in media
containing G418 prior to cisplatin treatment. Cell lysateChemotherapy Research and Practice 3
was obtained by lysing the cells in buﬀer (20mM HEPES
(pH 7.0), 1mM DTT, 1mM MnCl2, 100μg/mL BSA, and
50μM leupeptin) and performed for Western blot analysis.
2.4. siRNA-Mediated p53 Silencing Assay. Small interfering
RNAs (siRNAs) against p53 (SMARTpool p53) were pur-
chased from Upstate Biotechnology (Lake Placid, NY). The
siRNA Transfection Reagent Lipofectamine 2000 (Invitro-
gen) was used to transfect the siRNA into A2780 cells at a
ﬁnal concentration of 100nM. A negative nonspeciﬁc siRNA
was used as control. Twenty-four hours after transfection,
cells were treated with cisplatin for 1hr at IC50 dose. At the
end of 1hr exposure to cisplatin, cells were washed twice
and then incubated with fresh drug-free media for indicated
hours. The cells were harvested and protein level of p-Chk2,
Chk2, p-p53, p53, and P21 were determined by western
blotting.
2.5. Chk2 Transient Transfection. A2780 cells were trans-
fected with the plasmid pEF-BOS-HA, pEF-BOS-HA-Chk2,
or pEF-BOS-HA-Chk2D347A (provided by Dr. Jann N.
Sarkaria) for control or the expression of wild-type human
Chk2 or the expression of Chk2 kinase-dead point mutant.
Twenty-four hours after transfection, cells were treated with
cisplatin, and then were measured their expression levels.
2.6. Cytotoxicity Assay. A2780 or Caov-3 cells (around 1000
per well) were seeded in 96-well plates for 24hrs and
pretreated with diﬀerent concentrations of Chk2 inhibitor
II C3742 for 30min. Subsequently, cells were treated with
cisplatin at IC50 dose for 1hr while continuously exposed to
Chk2 inhibitor. After drug removal, cells were washed twice
with PBS, and then incubated with fresh medium containing
Chk2 inhibitor for 5 days. Cytotoxicity assay was performed
following company’s protocol of Cell Proliferation Kit I
(Roche) and the complete solubilization of the purple
formazan crystals was measured. Optical density was read at
600nm to determine cell quantity.
3.Results
3.1. Cisplatin Induced Phosphorylation of p53 and Chk2
in A2780 Cells. Human ovarian cancer A2780 cells were
analyzed for p53 mutations within exons 4 through 9 and
classiﬁed to p53 wild-type cell line (data not shown). A2780
cells were exposed to Cisplatin at 3μM( I C 50)f o r1h ,a n d
Western blotting was performed to analyze the levels of
selected proteins of DNA damage response pathway. We
observed increased protein level of ATM, p53, P48, and
P21 in a time-dependent manner (Figure 1). At 12h after
cisplatin treatment, the p53 level is highly accumulated,
accompanied by p53 phosphorylation. After drug treatment,
these cells demonstrated cisplatin-induced p53 phosphory-
lation at serine 15 and serine 20 and Chk2 phosphorylation
at Thr-68. Further, the greatest increase in p53 phospho-
rylation induced by cisplatin occurred 12 hours before the
primary increase in Chk2 phosphorylation, hinting that p53
activation occurs before Chk2. In addition, we observed that
A2780
C3 6 1 2 2 4 4 8
ATM
p-p53 (Ser15)
p-p53 (Ser20)
p53
p-Chk2(Thr68)
Chk2
P48
P21
β-actin
Post-CDDP(hr)
Figure 1: Cisplatin-induced DNA damage response in ovarian
cancer A2780 cells. A2780 cells were treated with 3μM cisplatin
(CDDP) for 1hr. Cells were then washed to remove cisplatin and
reincubated for indicated hours in a replacement of fresh drug-free
media. Cells were harvested, and proteins were extracted, separated
on SDS-PAGE gel, transferred onto PVDF membrane, and then
probed with antibodies of anti-ATM, anti-p-p53 (Ser15 & Ser20),
anti-p53, anti-p-Chk2 (Thr68), anti-Chk2, anti-P48, anti-P21 or
anti-β-Actin. β-Actin served as a control.
cisplatin-mediated activation of p53 resulted in activation of
downstream proteins P48 and P21 (Figure 1).
3.2. Overexpression of p53 in wt p53-Contain Cells Increased
Chk2 Phosphorylation. To determine the eﬀect of p53 reg-
ulation on Chk2 activation, we transfected the p53 wild-
type A2780 cells with plasmid pC53-SN3, which expresses
the wild-type human p53, and pCMV-Neo-Bam, which is
an empty vector of pC53-SN3. Twenty-four hours after
transfectioncellswere treatedwithcisplatinat3μM.Figure 2
shows that Chk2 phosphorylation is increased after p53
cDNA transfection. The overexpression of both p53 protein
and phosphorylated p53 in these cells by cisplatin induction
and cDNA transfection at least doubled the amount of
observed Chk2 phosphorylation 48 hours after cisplatin
stimulation.
3.3. Transfection of p53 in p53-Null Cells Failed to Alter
Chk2 Activation. We hypothesized that only the wt p534 Chemotherapy Research and Practice
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Figure 2: Overexpression ofp53 by p53 transfection in A2780cells.
A2780 cells were transfected with theplasmidpC53-SN3 orpCMV-
Neo-Bam for overexpression of wild-type humanp53. Twenty-four
hours after transfection, cells were treated with cisplatin (3μM)
for 1hr and then were continuously incubated with fresh media
for indicated hours. Cell lysate was obtained by lysing the cells
in lysate buﬀer and performed for Western blot analysis with
antibodies of anti-p-p53(Ser15), anti-p-p53(Ser20), anti-p53, anti-
p-Chk2(Thr68), anti-Chk2, anti-P21, or anti-β-Actin, respectively.
phenotype represents the p53 functional system. Therefore,
we transfected the plasmid of pC53-SN3and of pCMV-Neo-
Bam vector into SKOV3, p53-null cells. These cells were also
exposed to cisplatin after a 24-hour transfection. Western
analysis demonstrated no eﬀect of Chk2 phosphorylation
by p53 stable transfection (Figure 3(a))o rp 5 3t r a n s i e n t
transfection (Figure 3(b)). The similar expression pattern of
phosphorylated Chk2 induced by cisplatin alone was seen
in the three sample groups of control, negative, and positive
transfected cells. This indicates that cells without wt p53, to
survive, may adapt via an alternative pathway in response to
cisplatin treatment. In other words, cisplatin-induced Chk2
activation may be regulated following an alternative pathway
in the p53-null cells.
3.4. Inhibition of p53 by Speciﬁc siRNA Inhibited Chk2
Phosphorylation. We performed p53 knockoﬀ siRNA assay
using small interfering RNA (siRNA) to silence the p53
then determine Chk2 expression in A2780 cells. The siRNA
to human p53 contains 4 pooled SMART-selected siRNA
duplexes with “UU” overhangs and a 5  phosphate on
the antisense strand (Upstate Biotechnology). As shown in
Figure 4, in cells not treated with cisplatin, the siRNA to
human p53 produced a decrease of phosphorylated Chk2,
compared to the nonspeciﬁc siRNA-treated control. This
decreased level may reﬂect a constitutive level of activated
Chk2 68-phosphothreonine that is normally regulated by
p53. Cells transfected by speciﬁc siRNA to p53 and treated
with cisplatin resulted in a great reduction of p-Chk2
at Thr-68, suggesting that p53 modulates 68-threonine
phosphorylation of Chk2.
3.5. Transfection of Chk2 in wt p53 Cells Did Not Alter p53
Level. Hypothetically, overexpression of Chk2 should not
aﬀect p53 level. To investigate this, we transfected the wt
p53 A2780 cells with plasmid HA-Chk2, which expresses
wild-type Chk2 (Figure 5(a)), and with HA-Chk2D347A,
which is a kinase-dead Chk2 allele (Figure 5(b)). The empty
vectorwasalsotransfected,respectively,ascontrol.Cellswere
treated with cisplatin at IC50 dose 24h after transfection.
The results of Western blot analysis in these cells showed
no eﬀects of wild-type Chk2 (Figure 5(a))o rd e a dC h k 2
(Figure 5(b)) on p53 protein or p53 phosphorylation (both
Serine 15 and Serine 20). This suggests that Chk2 does
not have a regulative eﬀect on p53 in response to cisplatin
treatment in ovarian cancer cells.
3.6. Application of Chk2 Inhibitor in Combination with
Cisplatin Greatly Inhibited Cell Growth. Cytotoxicity Assay
was performed to validate our hypothesis that application of
Chk2 inhibitor potentiates cisplatin eﬃcacy in ovarian can-
cer treatment. Figure 6 shows that selective Chk2 Inhibitor
(C3742, Sigma) greatly increased the cell-killing eﬀect of
cisplatin in wt p53 A2780 cells (Figure 6(a)). In combination
with Chk2 inhibitor at 75μM, cisplatin produced about a 9-
fold inhibition on cell growth, compared to cisplatin alone.
This eﬀect appears to be more signiﬁcant (nearly 38-fold)
in the mutant p53, Caov-3 cells (Figure 6(b)). We conclude
that inhibition of Chk2 pathway with commercially available
inhibitor will enhance the therapeutic indices of platinum
compounds in the treatment of ovarian cancer, especially in
those defective for p53 function.
4.Discussion
Disruption of the mechanisms that regulate checkpoint and
apoptotic responses leads to genomic instability and the
development of cancer [20]. It is in the best interest of the
organism to prevent severely damaged cells from proliferat-
ing, eitherbyhalting themina phase ofcell cycleprogression
or by removing them entirely by apoptosis. The linear
pathway of ATM-Chk2-p53 has been the dominant model
and plays a central role in regulation of the cellular response
to DNA damage, resulting in cell cycle arrest, DNA repair,
or apoptosis depending on the cellular context and severity
of DNA damage. In a well-studied example during double-
strand-DNA-break damage, the ATM phosphatidylinositol
3-kinase-like serine/threonine protein kinase is activated
by autophosphorylation at the Ser1981 site [21]. Activated
ATM then phosphorylates several downstream substrates,
including Chk2 and p53 kinases. When the cell enters the
damage-repair process, phosphorylated p53 arrests the cell
cycle by inducing the expression of cell cycle inhibitors such
as p21 [21]. On the other hand, Chk2 contributes to p53
stabilization in response to IR [22], suggesting that Chk2
may, in this circumstance, be an upstream regulator of p53
[23]. In addition, the abundance of Chk2 mRNA was shown
to be inversely related to p53 status in human gastric cancer,
indicating the possibility that Chk2 is a downstream target
of the p53 [24–26]. Other evidence supports the model ofChemotherapy Research and Practice 5
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Figure3:Transfectionofp53inp53-nullSKOV-3cells.OvariancancerSKOV-3cellsweretransfected withtheplasmidpC53-SN3orpCMV-
Neo-Bam for 24hr: stable transfection (a) and transient transfection (b). Transfected cells were treated with cisplatin at IC50 dose (75μM)
for 1hr. The drug was removed by washing the cells with PBS. Cells were then incubated in fresh drug-free media for the indicated hours
(3, 6, 12, 24, and 48) up to harvest. Western blot analysis was performed with indicated antibodies. Nontransfected cells were treated with
cisplatin alone as control group.
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Figure 4: Inhibition ofp53 by speciﬁc siRNA to p53 in A2780 cells.
siRNA against p53 (SMARTpool p53) were transfected into A2780
cells using Lipofectamine 2000. A negative nonspeciﬁc siRNA was
used as control. Twenty-four hours after transfection, cells were
treated with cisplatin for 1hr at 3μM concentration. At the end
of 1hr exposure to cisplatin, cells were washed and incubated
with fresh media. The protein level of p-p53(Ser15), p-p53(Ser20),
p53, p-Chk2(Thr68), Chk2, p21, and β-Actin were determined by
Western blotting.
ATM-p53-Chk2, including: (a) Chk2 is not required for p53
responses in human cancer cells [27], (b) wild-type p53
suppresses mRNA and protein levels of Chk2 in human
osteosarcoma Saos2 (p53 null) cells [28], (c) p53 mutations
increase Chk2 expression in human gastric carcinoma [24],
(d) Chk2 is dispensable for p53-mediated G1 arrest but is
required for a latent p53-mediated apoptotic response [29],
and (e)Chk2 expression is negatively regulated by functional
p53, leading to a high level of expression in p53-deﬁcient
cancer cells [20, 30].
We observed that a cisplatin-induced increase in p53
phosphorylation preceded (by about 12 hours) the observed
increase in Chk2 phosphorylation. Overexpression of p53
in studied cells by cDNA transfection doubled the amount
of Chk2 phosphorylation 48 hours after cisplatin treatment,
whereas p53 knockdown by p53 speciﬁc siRNA greatly
reduced Chk2 phosphorylation. In contrast, overexpression
of Chk2 by transfection of wild-type Chk2 in these cells
did not show eﬀects on p53 protein or on phosphorylated
p53 (Ser15 and Ser20). These observations further deﬁne
the relationship between the two central mediators, p53
and Chk2. Our data suggest that in speciﬁc conditions
Chk2 activation by Thr68 phosphorylation is regulated by
p53 in response to cisplatin treatment in wt p53-contain
cells, but not in p53-deﬁcient cells, of human ovarian
cancer. In addition, transfection of p53 cDNA into p53-null
SKOV-3 cells failed to alter Chk2 activation, suggesting that
the Chk2 role occurs alternatively and p53 independently
in p53 defective cells. We conclude that wild-type p53,
in response to cisplatin stimulation, plays a role in the
upstream regulation of Chk2 phosphorylation at Thr-68.
Cells without normal p53 function survive via an alternative
pathway in response to the exogenous inﬂuence of cisplatin.
We strongly suggest that it is very important to include
the p53 mutational status in any p53 involved studies6 Chemotherapy Research and Practice
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Figure 5: Overexpression of Chk2 by transfection of wild-type Chk2 or Chk2 dead allele in A2780 cells. A2780 cells were transfected with
wild-type HA-Chk2 (a) or HA-Chk2 D347A (b) for overexpression of Chk2. Blank vectors were transfected as controls. Twenty-four hours
after transfection, cells were treated with cisplatin (3μM) for 1hr and then were incubated with fresh media. Cell lysate was obtained and
performed for Western blot analysis with antibodies of anti-p-p53(Ser15), anti-p-p53(Ser20), anti-p53, anti-p-Chk2(Thr68), anti-Chk2,
anti-p21, or anti-β-Actin, respectively.
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Figure 6: Application of Chk2 inhibitor in combination with cisplatin greatly inhibited cell growth. A2780 or Caov-3 cells (around 1000
per well) were seeded in 96-well plates for 24hrs and pretreated with diﬀerent concentrations of Chk2 inhibitor II C3742 for 30min.
Subsequently, cells were treated with cisplatin at IC50 dose for 1hr while continuously exposed to Chk2 inhibitor. After drug removal,
cells were washed twice with PBS, and then incubated with fresh medium containing Chk2 inhibitor for 5 days. Cytotoxicity assay was
performed following company’s protocol of Cell Proliferation Kit I (Roche) and the complete solubilization of the purple formazan crystals
was measured. Optical density was read at 600nm to determine cell quantity.
due to the functional diﬀerentiation of wt p53 and p53
mutant.
One of the approaches in current cancer treatment is
to identify drugs acting on speciﬁc cancer-relevant targets.
Speciﬁc sensitization of tumor cells to the action of genotox-
ins would reduce the eﬃcacious doses of genotoxins to be
used in patients, diminishing the detrimental side eﬀects of
the drugs on normal tissues [31, 32]. The checkpoint kinase
Chk2 is central to transmitting the DNA-damage signal.
Parallel studies of the human Chk2 gene have highlighted
its role as a candidate multiorgan tumor susceptibility gene
rather than a tumor suppressor gene in the classical sense.
Chk2 can prevent tumor progression by averting genomic
instability through DNA repair. If DNA-targeting agent
is combined with a Chk2 inhibitor, DNA repair will be
impaired and tumor cells unable to arrest the accumulation
of irreparable damaged DNA and consequently undergo
apoptosis [12]. Chk2 negatively regulate a poorly deﬁned
type of death occurring during mitosis or resulting from
failedmitosis(mitoticcatastrophe)byactivatingG2/Marrest
and preventing entry into mitosis, meaning that inhibition
of Chk2 may sensitize tumor cells to chemotherapy-induced
apoptosis [17]. In addition, Chk2 has been shown to induce
release from the mitochondria of the antiapoptotic proteinChemotherapy Research and Practice 7
survivin, which is thought to inhibit apoptosis in cancer cells
and might confer radiation resistance in human cancer cells
[18]. Chk2 elicits distinct cellular outcomes in the presence
orabsence ofextrinsic DNAdamagewithin aspeciﬁc cellular
context, in particular p53 status [12].
As stated earlier, the substrates of Chk2 kinase impact
both cell cycle checkpoint and apoptosis. In a p53-deﬁcient
tumor, Chk2 primarily aﬀects cell cycle checkpoint. Thus,
Chk2 inhibition would abrogate DNA damage-induced cell
cycle arrest and sensitize the tumor to chemotherapeutic
agents. In normal tissues, Chk2 acts as a proapoptotic
eﬀector; therefore, a Chk2 inhibitor would protect normal
tissues but sensitize the tumor to chemotherapeutic agents
[2, 12, 33]. Given the known role of Chk2 in ovarian cancer
pathogenesis and the ﬁndings from our studies and by other
groups, our goal is to block the Chk2-regulated DNA repair
pathwayusing aChk2inhibitortoenhance therapeuticindex
for current cancer chemotherapy.
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